Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Wayne Yeh, M.D.

Co-Author

This page shows the publications co-authored by Robert Yeh and Donald Cutlip.
Connection Strength

1.736
  1. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31; 70(18):2213-2223.
    View in: PubMed
    Score: 0.189
  2. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26; 315(16):1735-49.
    View in: PubMed
    Score: 0.170
  3. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26; 65(20):2211-21.
    View in: PubMed
    Score: 0.157
  4. Usefulness of postmarket studies to evaluate long-term safety of coronary eluting stents (from the ENDEAVOR and PROTECT Programs). Am J Cardiol. 2014 Aug 15; 114(4):528-33.
    View in: PubMed
    Score: 0.149
  5. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014 May 01; 83(6):975-83.
    View in: PubMed
    Score: 0.145
  6. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011 Oct 04; 124(14):1557-64.
    View in: PubMed
    Score: 0.123
  7. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681.
    View in: PubMed
    Score: 0.060
  8. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 12 15; 124(12):1813-1820.
    View in: PubMed
    Score: 0.054
  9. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 08 14; 40(31):2632-2653.
    View in: PubMed
    Score: 0.053
  10. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019 07 16; 140(3):240-261.
    View in: PubMed
    Score: 0.053
  11. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 08; 11(8):e005308.
    View in: PubMed
    Score: 0.050
  12. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 05 08; 10(9):942-954.
    View in: PubMed
    Score: 0.046
  13. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487.
    View in: PubMed
    Score: 0.046
  14. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 02; 135(18):1720-1732.
    View in: PubMed
    Score: 0.045
  15. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 04; 134(14):989-998.
    View in: PubMed
    Score: 0.043
  16. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31; 67(21):2492-502.
    View in: PubMed
    Score: 0.042
  17. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 03; 133(18):1772-82.
    View in: PubMed
    Score: 0.042
  18. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25; 9(2):138-47.
    View in: PubMed
    Score: 0.042
  19. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21; 37(4):378-85.
    View in: PubMed
    Score: 0.041
  20. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct; 8(12):1552-62.
    View in: PubMed
    Score: 0.041
  21. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015 Mar 17; 313(11):1113-21.
    View in: PubMed
    Score: 0.039
  22. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66.
    View in: PubMed
    Score: 0.038
  23. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 01; 113(7):1146-52.
    View in: PubMed
    Score: 0.036
  24. Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients. Stroke. 2012 Dec; 43(12):3218-24.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.